Martina Bonifazi1, Francesca Bravi2, Stefano Gasparini3, Carlo La Vecchia2, Armando Gabrielli4, Athol U Wells5, Elisabetta A Renzoni5. 1. Department of Epidemiology, Istituto di Ricerche Farmacologiche Mario Negri-Istituto di Ricovero e Cura a carattere Scientifico, Milan, Italy. Electronic address: martina.bonifazi@marionegri.it. 2. Department of Clinical Sciences and Community Health, Università Degli Studi di Milano, Milan, Italy. 3. Department of Biomedical Sciences and Public Health, Università Politecnica delle Marche, Ancona, Italy. 4. Department of Clinical and Molecular Sciences, Università Politecnica delle Marche, Ancona, Italy. 5. Interstitial Lung Disease Unit, Royal Brompton Hospital, Royal Brompton & Harefield NHS Foundation Trust, London, England.
Abstract
BACKGROUND: An increased cancer risk in patients with sarcoidosis has been suggested, although results are conflicting in a number of case-control and cohort studies. We conducted a systematic review of all available data and performed a meta-analysis to better define and quantify the association between sarcoidosis and cancer. METHODS: We searched Medline and Embase for all original articles on cancer and sarcoidosis published up to January 2013. Two independent authors reviewed all titles/abstracts to identify studies according to predefined selection criteria. We derived summary estimates using a random-effects model and reported them as relative risk (RR). Publication bias was evaluated using a funnel plot and was quantified by the Egger test. RESULTS: Sixteen original studies, involving > 25,000 patients, were included in the present review. The summary RR to develop all invasive cancers was 1.19 (95% CI, 1.07-1.32). The results for selected cancer sites indicated a significantly increased risk of skin (RR, 2.00; 95% CI, 1.69-2.36), hematopoietic (RR, 1.92; 95% CI, 1.41-2.62), upper digestive tract (RR, 1.73; 95% CI, 1.07-2.79), kidney (RR, 1.55; 95% CI, 1.21-1.99), liver (RR, 1.79; 95% CI, 1.03-3.11), and colorectal cancers (RR, 1.33; 95% CI, 1.07-1.67). There was no evidence of publication bias for all cancers (P = .9), nor for any specific cancer site. CONCLUSIONS: The present meta-analysis suggests a significant, though moderate, association between sarcoidosis and malignancy.
BACKGROUND: An increased cancer risk in patients with sarcoidosis has been suggested, although results are conflicting in a number of case-control and cohort studies. We conducted a systematic review of all available data and performed a meta-analysis to better define and quantify the association between sarcoidosis and cancer. METHODS: We searched Medline and Embase for all original articles on cancer and sarcoidosis published up to January 2013. Two independent authors reviewed all titles/abstracts to identify studies according to predefined selection criteria. We derived summary estimates using a random-effects model and reported them as relative risk (RR). Publication bias was evaluated using a funnel plot and was quantified by the Egger test. RESULTS: Sixteen original studies, involving > 25,000 patients, were included in the present review. The summary RR to develop all invasive cancers was 1.19 (95% CI, 1.07-1.32). The results for selected cancer sites indicated a significantly increased risk of skin (RR, 2.00; 95% CI, 1.69-2.36), hematopoietic (RR, 1.92; 95% CI, 1.41-2.62), upper digestive tract (RR, 1.73; 95% CI, 1.07-2.79), kidney (RR, 1.55; 95% CI, 1.21-1.99), liver (RR, 1.79; 95% CI, 1.03-3.11), and colorectal cancers (RR, 1.33; 95% CI, 1.07-1.67). There was no evidence of publication bias for all cancers (P = .9), nor for any specific cancer site. CONCLUSIONS: The present meta-analysis suggests a significant, though moderate, association between sarcoidosis and malignancy.
Authors: Eileen D Kuempel; Marie-Claude Jaurand; Peter Møller; Yasuo Morimoto; Norihiro Kobayashi; Kent E Pinkerton; Linda M Sargent; Roel C H Vermeulen; Bice Fubini; Agnes B Kane Journal: Crit Rev Toxicol Date: 2016-08-18 Impact factor: 5.635
Authors: Isabel Pascual-Camps; Nieves Alonso-Orcajo; Juan Pablo de la Fuente; Taygan Yilmaz; Miguel Cordero-Coma Journal: Int Ophthalmol Date: 2016-10-19 Impact factor: 2.031